A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Phase 3 Active not recruiting 21 enrolled Incyte Biosciences Japan GK

NaSingle-groupOpen-labelTreatment

Summary

This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).

Timeline

Start: 2024-07-30
Primary completion: 2025-08-06
Completion: 2027-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axatilimab	Monoclonal antibody	—	Intravenous

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Summary

Timeline

Drugs

Indications